Volume 115, Issue 6

Search all International Journal of Hematology articles

June 2022

Including PIH articles on Novel technologies and innovative treatments in multiple myeloma

Filter by

Volume:

Sort by

Date published:

New to old Old to new

21 articles in this issue

Obituary of Professor Fumimaro Takaku: a tribute to a real leader in medicine in Japan (1931–2022)
Akio Urabe
In Memoriam 24 May 2022 Pages: 759 - 759
Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma?
Hiroyuki Takamatsu
Progress in Hematology 11 May 2022 Pages: 760 - 761
Multiple myeloma with high-risk cytogenetics and its treatment approach
Ichiro Hanamura
Progress in Hematology Open access 09 May 2022 Pages: 762 - 777
Progress of modern imaging modalities in multiple myeloma
Toshiki Terao
Kosei Matsue
Progress in Hematology 09 May 2022 Pages: 778 - 789
Bringing mass spectrometry into the care of patients with multiple myeloma
David L. Murray
Progress in Hematology 26 April 2022 Pages: 790 - 798
Novel immunotherapies in multiple myeloma
Ken Ohmine
Ryosuke Uchibori
Progress in Hematology 18 May 2022 Pages: 799 - 810
Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group
Yuki Fujiwara
Tomohiro Urata
Yasushi Hiramatsu
Rapid Communication 18 May 2022 Pages: 811 - 815
T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia
Fumihiro Kawakami
Toru Kawakami
Fumihiro Ishida
Original Article 11 March 2022 Pages: 816 - 825
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19
Tomoko Onishi
Naruto Shimonishi
Keiji Nogami
Original Article 16 February 2022 Pages: 826 - 837
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
Naoto Takahashi
Jorge E. Cortes
Tim H. Brümmendorf
Original Article 02 March 2022 Pages: 838 - 851
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine
Akihito Matsuoka
Masaki Tanibuchi
Teruhisa Taoka
Original Article 11 March 2022 Pages: 852 - 859
Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors
Yoriko Yamashita-Kashima
Keigo Yorozu
Yasushi Yoshimura
Original Article 18 March 2022 Pages: 860 - 872
Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders
Yasushi Onishi
Koichi Onodera
Hideo Harigae
Original Article 10 March 2022 Pages: 873 - 881
The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors
Riko Tsumanuma
Eijiro Omoto
Hiromasa Yabe
Original Article 09 April 2022 Pages: 882 - 889
JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia
Yoshihiro Takahashi
Hisashi Ishida
Keizo Horibe
Original Article 08 March 2022 Pages: 890 - 897
Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation
Chie Asou
Tomoya Maeda
Norio Asou
Case Report 28 January 2022 Pages: 898 - 901
Bosutinib-induced lung injury: a report of two cases and literature review
Naoki Watanabe
Tomoiku Takaku
Miki Ando
Case Report 28 February 2022 Pages: 902 - 905
Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab: a case report
Fuko Kawahara
Rie Shirayama
Koichi Kusuhara
Case Report 25 January 2022 Pages: 906 - 912
Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination
Tohru Inaba
Keita Okumura
Yoko Nukui
Letter to the Editor 12 April 2022 Pages: 913 - 914
Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations
Gerold Thölking
Ulrich Jehn
Stefan Reuter
Letter to the Editor 09 April 2022 Pages: 915 - 915
Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination
Tohru Inaba
Keita Okumura
Yoko Nukui
Correction 05 May 2022 Pages: 916 - 917

Volume 115, Issue 6

Obituary of Professor Fumimaro Takaku: a tribute to a real leader in medicine in Japan (1931–2022)

Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma?

Multiple myeloma with high-risk cytogenetics and its treatment approach

Progress of modern imaging modalities in multiple myeloma

Bringing mass spectrometry into the care of patients with multiple myeloma

Novel immunotherapies in multiple myeloma

Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group

T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia

The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis

Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors

Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders

The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors

JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia

Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation

Bosutinib-induced lung injury: a report of two cases and literature review

Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab: a case report

Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination

Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations

Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination

Navigation